Condition: Multiple Sclerosis · Multiple Sclerosis, Primary Progressive · Multiple Sclerosis, Secondary Progressive · Sponsor: Stanford University
A Study of Anti-CD19 Chimeric Antigen Receptor T Cell Therapy in Subjects with Non-relapsing and Progressive Forms of Multiple Sclerosis
This description comes directly from the study's public registry record.
Multiple Sclerosis and Neuroimmunology Study Team · 650-387-5907 · neuroimmunologyresearch@stanford.edu
Always discuss trial participation with your own doctor first.
| Stanford Multiple Sclerosis Center | Palo Alto, California, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06138132